secwatch.observer — SEC 8-K summary
======================================

Issuer:     Candel Therapeutics, Inc. (CADL)
CIK:        0001841387
Form:       8-K
Filed at:   2026-02-23T23:59:59+00:00
Accession:  0001193125-26-062490
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Candel Therapeutics prices $100M public offering of 18.3M shares at $5.45/share
-------------------------------------------------------------------------------

- Gross proceeds $100M from 18,348,624 shares at $5.45; net ~$93.5M base, up to ~$107.6M if option exercised.
- Funds will support launch readiness, medical affairs, pre-commercialization for CAN-2409 in early localized prostate cancer and phase 3 trial in NSCLC.
- Underwriters granted 30-day option to purchase up to 2,752,293 additional shares at same price.
- Offering expected to close Feb 23, 2026; Citigroup, Cantor, Stifel are joint bookrunners.
- Pro forma cash runway extended into Q1 2028 based on base net proceeds.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1841387/000119312526062490/0001193125-26-062490-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1841387/000119312526062490/d113082d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-062490

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer